Open Access
| Issue |
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 997 - 1000 | |
| Section | Anticorps nus et monospécifiques en cancérologie : quels autres progrès depuis 2009 ? | |
| DOI | https://doi.org/10.1051/medsci/2019197 | |
| Published online | 06 January 2020 | |
- Lacour B, Guyot-Goubin A, Guissou S, et al. Incidence of childhood cancer in France: nnational children cancer registries, 2000–2004. Eur J Cancer Prev 2010 ; 19: 173–181. [CrossRef] [PubMed] [Google Scholar]
- Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010 ; 363: 1324–1334. [Google Scholar]
- Ladenstein R, Poetschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 2018 ; 19: 1617–1629. [CrossRef] [PubMed] [Google Scholar]
- Lode HN, Valteau-Couanet D, Garaventa A, et al. Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients. J Clin Oncol 2015 ; 33: 10080. [Google Scholar]
- Mueller I, Ehlert K, Endres S, et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO. MAbs 2018; 10: 55–61. [CrossRef] [PubMed] [Google Scholar]
- Ladenstein R, Poetschger U, Valteau-Couanet D, et al. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: early results from the HR-NBL1/SIOPEN trial. J Clin Oncol 2019; 37 (abstract 10013). [Google Scholar]
- Ladenstein R, Poetschger U, Valteau-Couanet D, et al. Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within theHR-NBL1/SIOPEN trial improves outcome of high-risk neuroblastoma patients compare to historical controls. J Clin Oncol 2018; 36 (suppl 15): 10539. [Google Scholar]
- Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol 2017 ; 18: 946–957. [CrossRef] [PubMed] [Google Scholar]
- Furman WL, Shulkin BL, Federico SM, et al. Early response rates and Curie scores at end of induction: an update from a phase II study of an anti-GD2 monoclonal antibody with chemotherapy in newly diagnosed patients with high-risk neuroblastoma. J Clin Oncol 2017; 35 (abstract 10534). [Google Scholar]
- Terme M, Dorvillius M, Cochonneau D, et al. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS One 2014 ; 9: e87210. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.